fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether and aprepitant

fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether has been researched along with aprepitant in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Krishnan, R; Ranga, K	1

Trials

1 trial(s) available for fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether and aprepitant

Article	Year
Clinical experience with substance P receptor (NK1) antagonists in depression. The Journal of clinical psychiatry, 2002, Volume: 63 Suppl 11 Topics: Antidepressive Agents; Anxiety Disorders; Aprepitant; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Ethers; Female; Humans; Hydrocarbons, Fluorinated; Male; Morpholines; Neurokinin-1 Receptor Antagonists; Paroxetine; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Substance P; Treatment Outcome	2002

Article

Year

Clinical experience with substance P receptor (NK1) antagonists in depression.

The Journal of clinical psychiatry, 2002, Volume: 63 Suppl 11

Topics: Antidepressive Agents; Anxiety Disorders; Aprepitant; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Ethers; Female; Humans; Hydrocarbons, Fluorinated; Male; Morpholines; Neurokinin-1 Receptor Antagonists; Paroxetine; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Substance P; Treatment Outcome

2002